Gilead(US:GILD) Xin Hua She·2025-10-28 23:25Core Points - South Africa has officially approved the new long-acting injectable HIV prevention drug, Lenacapavir, making it the first country in Africa to do so [1] - The drug, developed by Gilead Sciences, requires only two injections per year, providing up to six months of immune protection against HIV [1] - The South African government plans to launch the drug by March 2026, aiming to significantly reduce the annual treatment cost through agreements with Gilead and seven other pharmaceutical companies [1] - Lenacapavir is considered the most effective HIV prevention drug to date, which is particularly significant for South Africa, where the HIV infection rate is high [1] - The FDA has already approved Lenacapavir for HIV prevention in the United States, with a market price of $28,000 per person per year [1]